Clinical Trial · NCT04457232

Prospective Exploratory Study of FAPi PET/CT in Prostate Cancer With Histopathology Validation

Overview

This exploratory study investigates how a new imaging technique called FAPI PET/CT can determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and cancer tissues in patients with prostate cancer. Because some cancers take up 68Ga-FAPi-46 it can be seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that surround tumors. The function of FAP is not well understood but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with FAPI PET/CT may in the future provide additional information about various cancers including prostate cancer.

Sponsor

Jonsson Comprehensive Cancer Center (UCLA)

Phase

Phase 1

Contacts

Jeremie Calais (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT04457232

Drug / Compound

FAPI-46

Isotope(s):

Target(s):

Ligand Class: Small Molecules

Chelator: DOTA

PSMA-11

Isotope(s):

Target(s):

PSMA

Ligand Class: Small Molecules

Chelator: HBED-CC

Eligibility

Inclusion

Patients who underwent a 68Ga-PSMA-11 PET/CT scan within 3 months of enrollment
Patients are able to remain still for duration of imaging procedure (up to one hour)
Patients who are scheduled to undergo surgical excision or biopsy of a prostate cancer primary, recurrent or metastatic lesion

Exclusion

Patients with any new prostate therapy between the PSMA PET/CT and the FAP inhibitor (FAPI) PET/CT

Patient Education

Patient education not yet provided.

Publications

Publications not yet provided.

Locations

Loading…